What question did this study set out to answer?

Characterise the population and molecular features of KRAS wild type pancreatic ductal adenocarcinoma.

Characteristics of KRAS WT pancreatic adenocarcinomas: results of a large French multicentric cohort

View Full Paper

Ask AI

Bookmark

Authors

Clinical data shows molecular abnormalities in KRAS WT pancreatic adenocarcinomas, highlighting therapeutic approaches for improved outcomes.

Characterise the population and molecular features of KRAS wild type pancreatic ductal adenocarcinoma.
Retrospective analysis of a large cohort of KRAS WT PDAC patients
Utilised next-generation sequencing for DNA and RNA analysis
Examined clinical data alongside molecular characteristics
Identified 93 KRAS WT PDACs out of 1059 cases (9%)
Eight cases exhibited druggable fusions
19 cases had mutations in homologous recombination genes
No significant clinical outcome differences noted between KRAS WT and KRAS-mutated tumours

Trystram et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Clinical data shows molecular abnormalities in KRAS WT pancreatic adenocarcinomas, highlighting therapeutic approaches for improved outcomes.